BACKGROUND: Identifying genetic factors that influence poxvirus immunity across races may assist in the development of better vaccines and approaches for vaccine development. METHODS: We performed an extensive candidate-gene genetic screen (across 32 cytokine and cytokine receptor genes) in a racially diverse cohort of 1056 healthy adults after a single dose of smallpox vaccine. Associations between single-nucleotide polymorphisms (SNPs)/haplotypes and vaccinia virus-specific neutralizing antibodies were assessed using linear regression methodologies. RESULTS: The combined analysis identified 63 associations between candidate SNPs and antibody levels after smallpox vaccination with P < .05. Thirty-one of these were within the IL18R1 and IL18 genes. Five IL18R1 SNPs, including a coding synonymous polymorphism rs1035130 (Phe251Phe) and 2 promoter SNPs (rs6710885, rs2287037), all in linkage disequilibrium, were associated with significant variations in antibody levels in both Caucasians (P ≤ .016) and African Americans (P ≤ .025). Similarly, associations with 2 intronic IL18 SNPs (rs2043055 and rs5744280) were consistent in the Caucasian (P ≤ .023) and African American samples (P ≤ .014). Haplotype analysis revealed highly significant associations between IL18R1 haplotypes and vaccinia virus-specific antibody levels (P < .001, by combined analysis) that were consistent across races. CONCLUSIONS: Our study provides evidence for IL18 and IL18R1 genes as plausible genes regulating the humoral immune response to smallpox vaccine in both Caucasians and African Americans.
BACKGROUND: Identifying genetic factors that influence poxvirus immunity across races may assist in the development of better vaccines and approaches for vaccine development. METHODS: We performed an extensive candidate-gene genetic screen (across 32 cytokine and cytokine receptor genes) in a racially diverse cohort of 1056 healthy adults after a single dose of smallpox vaccine. Associations between single-nucleotide polymorphisms (SNPs)/haplotypes and vaccinia virus-specific neutralizing antibodies were assessed using linear regression methodologies. RESULTS: The combined analysis identified 63 associations between candidate SNPs and antibody levels after smallpox vaccination with P < .05. Thirty-one of these were within the IL18R1 and IL18 genes. Five IL18R1 SNPs, including a coding synonymous polymorphism rs1035130 (Phe251Phe) and 2 promoter SNPs (rs6710885, rs2287037), all in linkage disequilibrium, were associated with significant variations in antibody levels in both Caucasians (P ≤ .016) and African Americans (P ≤ .025). Similarly, associations with 2 intronic IL18 SNPs (rs2043055 and rs5744280) were consistent in the Caucasian (P ≤ .023) and African American samples (P ≤ .014). Haplotype analysis revealed highly significant associations between IL18R1 haplotypes and vaccinia virus-specific antibody levels (P < .001, by combined analysis) that were consistent across races. CONCLUSIONS: Our study provides evidence for IL18 and IL18R1 genes as plausible genes regulating the humoral immune response to smallpox vaccine in both Caucasians and African Americans.
Authors: Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland Journal: Am J Hum Genet Date: 2001-12-27 Impact factor: 11.025
Authors: Tania Azam; Daniela Novick; Philip Bufler; Do-Young Yoon; Menachem Rubinstein; Charles A Dinarello; Soo Hyun Kim Journal: J Immunol Date: 2003-12-15 Impact factor: 5.422
Authors: Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson Journal: Am J Hum Genet Date: 2003-12-15 Impact factor: 11.025
Authors: A-M Martin; G Athanasiadis; J D Greshock; J Fisher; M P Lux; K Calzone; T R Rebbeck; B L Weber Journal: Hum Hered Date: 2003 Impact factor: 0.444
Authors: Jody Manischewitz; Lisa R King; Nicole A Bleckwenn; Joseph Shiloach; Rolf Taffs; Michael Merchlinsky; Nancy Eller; Malgorzata G Mikolajczyk; David J Clanton; Thomas Monath; Richard A Weltzin; Dorothy E Scott; Hana Golding Journal: J Infect Dis Date: 2003-07-16 Impact factor: 5.226
Authors: Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Robert M Jacobson; Gregory A Poland Journal: Hum Genet Date: 2012-06-03 Impact factor: 4.132
Authors: Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Beth R Larrabee; V Shane Pankratz; Gregory A Poland Journal: Hum Immunol Date: 2013-06-24 Impact factor: 2.850
Authors: Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Gregory A Poland Journal: Hum Genet Date: 2012-05-19 Impact factor: 4.132
Authors: Inna G Ovsyannikova; V Shane Pankratz; Hannah M Salk; Richard B Kennedy; Gregory A Poland Journal: Hum Genet Date: 2014-06-01 Impact factor: 4.132
Authors: Eric K Dumas; Melissa L Nguyen; Philip M Cox; Heidi Rodgers; Joanne L Peterson; Judith A James; A Darise Farris Journal: Vaccine Date: 2013-02-13 Impact factor: 3.641
Authors: Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Megan M O'Byrne; V Shane Pankratz; Gregory A Poland Journal: J Infect Dis Date: 2013-07-30 Impact factor: 5.226
Authors: Whitney L Simon; Hannah M Salk; Inna G Ovsyannikova; Richard B Kennedy; Gregory A Poland Journal: Immunotherapy Date: 2014 Impact factor: 4.196
Authors: Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Gregory A Poland Journal: Gene Date: 2012-08-23 Impact factor: 3.688